In this episode, Dr. Orkin discusses results from key studies reported at AIDS 2020: Virtual, with new data on the following hot topics: current ART in principal populations, including older patients and women who become pregnant; metabolic outcomes during ART; HIV and COVID-19; investigational ART strategies; and HIV prevention. The overview includes: The ADVANCE trial comparing initial ART with DTG plus FTC/TAF, DTG plus FTC/TDF, or EFV/FTC/TDFA pooled analysis of randomized trials evaluating a switch to BIC/FTC/TAF in patients 65 years of age or older with virologic suppression on their current ARTA Kaiser Permanente study of BMI changes over time following ART initiation An analysis of the longitudinal prospective OPERA cohort that assessed weight change with switch from TDF to TAFMetabolic changes with switch from 3- or 4-drug TAF-based ART to 2-drug DTG/3TC in the TANGO studyUpdated findings from the Tsepamo birth surveillance study in Botswana evaluating the prevalence of neural tube defects by antiretroviral exposure during conception/pregnancyA retrospective study of COVID-19 in people with HIV presenting at 5 New York City Emergency Departments from March 2 to April 15, 2020An analysis of protocol-defined virologic failure in the P011 study comparing islatravir plus DOR vs DOR/3TC/TDF in treatment-naive adultsA study evaluating the lenacapavir pharmacokinetic profileResults from the HPTN 083 trial investigating the efficacy and safety of long-acting injectable cabotegravir vs daily oral TDF/FTC for PrEP in MSM and TGWPresenter:Chloe Orkin, MBChB, FRCP, MDProfessor of HIV Queen Mary, University of LondonConsultant PhysicianLead for HIV Research Barts Health NHS TrustThe Royal London HospitalLondon, United KingdomContent based on a CME program supported by independent educational grants from Gilead Sciences, Merck Sharp & Dohme Corp., and ViiV Healthcare.Link to full program: https://bit.ly/33YRz0t